BCL2 and acute myeloid leukemia: Venetoclax/ABT199 (VEN) is a Bcl-2-specific inhibitor, clinically approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [1, 3, 4].